Abstract
heart failure manifests clinically. High mortality due to cardiac hemosiderosis suggests that the condition is not recognized until the advanced stage of the disease. By that time it is too late for effective intervention. 6 Regular and adequate iron-chelation therapy can prevent and improve cardiac dysfunction in TM patients. 7-8 Several iron-chelating agents are available, but controversies remain on which iron-chelating agents better preserve cardiac function.
DFP, as the world's first oral iron-chelating agent, has been affinity to plasma free iron. DFP is a bidentate chelator with a lower molecular weight than that of DFO (only more easily penetrate cells to bind intracellular free iron.
The gold standard tool for detecting cardiac echocardiography remains the preferred method of evaluation. [23] [24] [25] signals are from myocardial wall movement. [26] [27] [28] Aypar et al. sensitivity and specificity when correlated with T2* with normal systolic function. The objective of this study was to compare the proportion of cardiac dysfunction in TM patients who had used subcutaneous DFO to those who used oral DFP as iron-chelating agents. DFP subjects abnormalities than DFO subjects.
Methods
This cross-sectional study was conducted at the years with a mean pre-transfused hemoglobin level congenital heart disease or overt heart failure were The required sample size was calculated by hypothesis testing against a two proportion formula (  -P 2  This since left-sided heart failure is more common than right-sided heart failure in young populations, and five-fold more common than right-sided heart failure in TM patients. parameters were used, including ejection fraction used were Sa (myocardial velocity in cm/s during and mid-lateral left ventricular locations. [32] [33] [34] [35] [36] [37] determined based on receiver operating characteristic subjects. The presence of systolic dysfunction was echocardiography parameters could not be used to determine grade of systolic dysfunction.
point criteria was based on Ea value, which correlated predicting cardiac hemosiderosis in a study by Aypar et al
We determined the presence of diastolic low Ea both groups. The cardiac dysfunction test results of the left side of the heart by iron chelator groups is described in Table 3 and Table 4 .
The majority of subjects had both diastolic and total subjects had systolic dysfunction only, and only this study, the proportion of subjects with subclinical cardiac dysfunction were not significantly different between the DFO and DFP groups.
determined by E/Ea ratio and E/A ratio as shown in Table 1 .
Results
subjects in the DFO group and 38 subjects in the DFP group. Table 2 describes the subjects' characteristics of Discussion male subjects, the ratio of DFP to DFO use was was preferred over the subcutaneous chelator, because the oral route is more practical, more comfortable, non-invasive and not painful. DFP requires no special administration procedure nor restriction of daily activities. Patients' compliance to the oral chelator was better than that of the subcutaneous chelator, hence there were fewer DFO users. The mean ages for the DFO and DFP groups
Longer duration of illness and and greater number of hemosiderosis. Serum ferritin in ranges within the iron-chelating agent used, had severe iron overload study by Silvilairat et al. 42 reported that increasing E/ Ea ratio reflects severe cardiac iron overload. They also showed that cardiac function in TM subjects mL. However, we found that nine subjects with mean already had cardiac abnormalities. The lowest serum boy who had ß-major thalassemia for 8.3 years and had 46 reported that patients had better compliance with DFP than with DFO use. We also found that patient compliance was slightly better with the oral chelator than the subcutaneous chelator, although this difference was not statistically nor clinically patient education about their illness and its long-term complications, including cardiac hemosiderosis, is needed to motivate them to comply in taking the iron-chelating agents.
echocardiography could have been diastolic, systolic, or a combination of both diastolic and systolic dysnormal global cardiac function in the majority of -cant cardiac dysfunction in the majority of subjects.
all subjects, while systolic dysfunction was detected presence of either diastolic or systolic dysfunction was not significantly different between the two groups (all both chelator groups, diastolic dysfunction was more commonly seen than systolic dysfunction.
A decrease in the regional myocardial wall velocity was typically found before any signs and symptoms of early detection of regional abnormalities before global in estimating the left ventricle end diastolic pressure 8 correlates with an elevation of LVEDP, according to Ommen et al. 47 who correlated direct measurement of LVEDP through an invasive cathetherization procedure and E/Ea ratio by echocardiography. An increase in E/ Ea ratio has been correlated to an increased clinical risk of heart failure. 28 to ineffective erythropoiesis, peripheral hemolysis, and an increase in iron absorption through the gastrointestinal tract, but the main cause is repetitive mg of iron. Repetitive transfusions saturate the body's to cell structures, apoptosis of cardiomyocytes, and eventually cardiac dysfunction. commonly seen than systolic dysfunction, similar to several other thalassemia studies [48] [49] [50] [51] [52] in which left ventricle diastolic dysfunction usually preceded the onset of systolic dysfunction. Diastolic dysfunction in our subjects was classified as mainly moderate ratio. This "normal" E/A ratio in moderate diastolic dysfunction was a pseudo-normal pattern, because E/Ea ratio was increased when measured by the could not be used alone to detect moderate diastolic "normal" E/A ratios found by the conventional method, hence leading to different echocardiogram interpretations.
dysfunction only was seen in 6/38 subjects, both while 2/38 subjects had normal cardiac function. The occurrence of cardiac dysfunction, diastolic or systolic, between the two iron-chelator groups were not DFP group than in the DFO group, but this was not the case. One reason could be that the majority of DFO users had changed to DFP use after its introduction changed their chelating agent from DFO to DFP. is possible that subjects' cardiac dysfunction occured before the change in iron chelators. Furthermore, subclinical cardiac dysfunction may occur before patients enter their second decade of life, but we only them according to the chelator they had taken by in the year prior to the study.
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damage in their heart tissue due to iron overload. Differences at molecular level and in immunogenetic mechanisms influence the body's resistance to iron
The majority of subjects in our study had significant subclinical cardiac dysfunction. Early recognition of these abnormalities before obvious clinical manifestations are seen is important in order to intervene earlier. Optimizing chelation therapy could reverse these abnormalities as much as possible in order to gain better quality of life and increase patients' survival rates.
Since this study was not longitudinal, all factors that might interact and influence the occurrence of cardiac dysfunction, as well as a cause-result for protecting cardiac function, a longitudinal study must be done with all participants observed from the first time they receive chelation therapy, at a certain standard dosage, and then monitored regularly until they enter the second decade of life without any small sample size, especially in the DFO group, compliance levels were assessed only by interviewing subjects and their parents, which may be subject to recall bias.
was detected in the majority of TM subjects, but with between the iron chelator groups was not significantly different. Among all thalassemia major patients 
